NBIX News and Press, Neurocrine Biosciences Inc. From 05/28/24

2024-05-28 17:04:47 ET Gainers: Blue World Acquisition  ( BWAQ ) +57% . Insmed  ( INSM ) +33% . Vivid Seats  ( SEAT ) +8% . Ocular Therapeutix ( OCUL ) +7% . Mind Medicine  ( MNMD ) +7% . Losers: Inhib...

2024-05-28 16:30:06 ET More on Neurocrine Biosciences Neurocrine Biosciences, Inc. (NBIX) Q1 2024 Earnings Call Transcript Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data Neurocrine Q1 revenue beats Street, gets FDA okay for Ingrezza Sprinkl...

Neurocrine Biosciences Announces CEO Succession Plan PR Newswire Board of Directors appoints Kyle Gano , Ph.D., Chief Business Development and Strategy Officer, as CEO-elect, effective October 11, 2024 Kevin Gorman , Ph.D., to continue to serve on the ...

Neurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024 PR Newswire New CAHtalyst™ Pediatric and CAHtalyst!...

2024-05-28 07:00:15 ET Ashwani Verma from UBS issued a price target of $193.00 for NBIX on 2024-05-28 05:23:00. The adjusted price target was set to $193.00. At the time of the announcement, NBIX was trading at $139.4. The overall price target consensus is at $136.41 wit...

2024-05-25 10:24:03 ET More on AbbVie, Amgen, etc. Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors Amgen Stock: Poised To Break Out (Techni...

Neurocrine Biosciences Announces Publication of Phase 3 KINECT®-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA® (valbenazine) Capsules PR Newswire SAN DIEGO , May 21, 20...

2024-05-21 06:37:29 ET Summary Invesco S&P MidCap Momentum ETF had a strong performance, up over 21% in 2023 and 29% YTD. The S&P MidCap 400 index has consistently outperformed the S&P 500. Momentum stock selection works and is augmented in the Mid-cap asset class,...

2024-05-14 11:24:32 ET More on BioNTech, Moderna, etc. BioNTech SE 2024 Q1 - Results - Earnings Call Presentation BioNTech SE (BNTX) Q1 2024 Earnings Call Transcript Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks Moderna announces del...

Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024 PR Newswire - CAHtalyst™ Phase 3 Baseline Characteristics Highlight Limitatio...